Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
Authors
Keywords
Heart failure, Type 2 diabetes mellitus, Sodium glucose co-transporter 2 inhibitors dipeptidyl peptidase-4 inhibitor
Journal
Cardiovascular Diabetology
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-23
DOI
10.1186/s12933-018-0737-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Heart failure 2016: still more questions than answers
- (2017) Marco Metra et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
- (2017) Atsushi Tanaka et al. Journal of Cardiology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
- (2016) Hiroyuki Tanaka et al. ADVANCES IN THERAPY
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
- (2016) Kristian B. Filion et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
- (2015) Yuliya Lytvyn et al. Canadian Journal of Diabetes
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Uric acid and risk of heart failure: a systematic review and meta-analysis
- (2013) He Huang et al. EUROPEAN JOURNAL OF HEART FAILURE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of uric acid with mortality in patients with stable coronary artery disease
- (2012) Gjin Ndrepepa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started